

Personalized Medicine and Companion Diagnostic Market Q2 2013- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

<https://marketpublishers.com/r/P40B3A29BD7EN.html>

Date: July 2013

Pages: 205

Price: US\$ 3,400.00 (Single User License)

ID: P40B3A29BD7EN

Abstracts

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 261 tables & figures over 205 pages. The personalized medicine (global) market is presented as follows:

By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)

By Geography (US, UK, EU)

By Segment (Targeted therapeutics, Companion Diagnostics, Esoteric tests, Esoteric lab services)

By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics)

A wealth of financial data & business strategy information is provided including:

Up-to-date company financials, sales & revenue figures

Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies

Business Model Strategies for Providers. Provider Systems and Academic

Medical Centres

Business Model Strategies for Payers & Governments

Private and Public Funding and Personalized Medicine Reimbursement

Revisions to Current Payment Systems and intellectual property

How to Gain Market Penetration in the EU

Cost-effectiveness and Business Value of Personalized Medicine

Consumer genomics and POC market

Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)

Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

Key strengths, weaknesses and threats influencing leading player position within the market

Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)

Top fastest growing market segments and emerging opportunities

Top pharmaceutical companies within the IPM by market share and revenue

Comprehensive product portfolios, R&D activity and pipeline therapeutics

M&A activity and future strategies of top personalized medicine pharmacos

Personalized Medicine Regulation (UK, Germany, France, Spain, Italy)

CE-marked Personalized Medicine/Diagnostic Tests

FDA Advances in Personalized Medicine Regulation

This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy.

23andMe

Affymetrix

Astex Pharmaceuticals

Atossa Genetics

CuraGen

Celera Corporation (Quest Diagnostics)

Celldex Therapeutics

deCode Genetics (Amgen)

Illumina

Genelex

Myriad

Nodality

Qiagen

What you will gain:

An in-depth understanding of the global personalized medicine market and it's environment

Current market facts, figures and product lines of key players in the industry

Emerging trends in key markets such as the US, UK, Germany and France

Knowledge of how the personalized medicine market will integrate into the global healthcare market

Technical insights into new generation sequencing technologies and ultra-high throughput sequencing

Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies

FDA approved pharmacogenetic tests and recognized biomarkers

Information on key government and regulatory policies

Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the personalized medicine market such as:

Lack of regulatory policy and legislation in the US and Europe

Reimbursement schemes and payers concerns

Transition of investigational diagnostic assays and therapeutics to clinical practice

Direct to consumer (DTC) test kits and implications for the public

Who should read this report?

Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine

Industry professionals and business strategists will discover key information to

propel their policies

Investors will gain inside information to dominant players in the industry and future forecasts

Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

This report will tell you if the companies mentioned are:

Strong, competitive players

Pooling their resources for specific growth and therapeutic areas

Investing strategically in R&D

Have a history of strategic M&A activity

This detailed report is supported with 261 figures and tables over 205 pages and profiles the main pharmacos in personalized medicine.

Contents

1 EXECUTIVE SUMMARY

- 1.1 Objectives of Report
- 1.2 Scope of Study
- 1.3 Data Sources and Methodology
- 1.4 Key Findings and Observations

2 INTRODUCTION

- 2.1 Pharmacogenetics
- 2.2 How Personalized Medicine Monitoring can Reduce Adverse Drug Reactions
- 2.3 Pharmacogenetic Study Challenges
- 2.4 Pharmacogenomics
- 2.5 Applications of Pharmacogenomics
 - 2.5.1 Pharmacogenomics: Improving the Safety of Medications
 - 2.5.1.1 Adverse Drug Reactions
 - 2.5.1.2 Pharmacogenomics: Improving the Efficacy of Therapeutics
- 2.6 Pharmacogenetic Analysis
 - 2.6.1 Single Base Primer Extension
 - 2.6.2 Primer Based Base Extension
 - 2.6.3 Hybridization Based SNP Analysis
 - 2.6.4 Ligation Based Approach
 - 2.6.5 New-Generation Sequencing Technologies
 - 2.6.6 Ultra-High Throughput Sequencing
- 2.7 Companion Diagnostics

3 PERSONALIZED MEDICINE THERAPEUTICS AND COMPANION DIAGNOSTICS

- 3.1 CYP2C9 and VKORC1 mutations and Warfarin Response
- 3.2 HLA-B*5701 and Abacavir Response
- 3.3 KRAS Mutations
 - 3.3.1 Erbitux
 - 3.3.2 Vectibix
- 3.4 Herceptin® and Breast Cancer
- 3.5 BRACAnalysis®
 - 3.5.1 Comprehensive BRACAnalysis®
 - 3.5.2 BRACAnalysis® Rearrangement Test (BART)

- 3.5.3 Single Site BRACAnalysis®
- 3.5.4 Multisite 3 BRACAnalysis®
- 3.6 Oncotype Dx Test

4 PERSONALIZED MEDICINE AND INTEGRATION INTO THE HEALTHCARE SYSTEM

- 4.1 The Personalized Medicine Coalition
- 4.2 Personalized Medicine and the Healthcare System
- 4.3 Clinical Application of Personalized Medicine
- 4.4 Clinical Laboratory Improvement Amendments-Certified Laboratory of Genomic Pathology

5 PRIVATE AND PUBLIC FUNDING AND PERSONALIZED MEDICINE REIMBURSEMENT

- 5.1 International Research and Development Personalized Medicine Activity
 - 5.1.1 Publically Funded Personalized Medicine Research
 - 5.1.2 Privately Funded Personalized Medicine Research
- 5.2 Popular Biological Targets/Pathways in Pharmacogenetic/Pharmacogenomic Research
- 5.3 Equitable Payer Reimbursement
 - 5.3.1 Molecular Diagnostic Payments in Personalized Medicine
 - 5.3.1.1 RVU-CPT-ICD Coding System
 - 5.3.2 Laboratory Service Payments in Personalized Medicine
 - 5.3.3 Revisions to Current Payment System
- 5.4 Biorepositories and Biobanks
- 5.5 Intellectual Property and Personalized Medicine

6 EUROPEAN PERSONALIZED MEDICINE MARKET – PAYMENTS AND INVESTMENT

- 6.1 Personalized Medicine and The European Market
- 6.2 European Investment in Personalized Medicine
- 6.3 Overview of Reimbursement Policies in Europe
- 6.4 Gaining Market Penetration in the EU
- 6.5 Personalized Medicine Regulation and Reimbursement in the UK
- 6.6 CE-marked Personalized Medicine/Diagnostic Tests in the UK
- 6.7 Personalized Medicine Regulation in Germany

- 6.8 Personalized Medicine Regulation in France
- 6.9 Personalized Medicine Regulation in Spain
- 6.10 The Personalized Medicine Regulation in Italy
- 6.11 Challenges of Future Personalized Medicine Development

7 PERSONALIZED MEDICINE –BUSINESS MODEL ANALYSIS

- 7.1 New Business Model Required for Personalized Medicine
- 7.2 Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies
- 7.3 Business Model Strategies for Providers. Provider Systems and Academic Medical Centres
- 7.4 Business Model Strategies for Payers
- 7.5 Business Model Strategies for Governments
- 7.6 Introduction of Non-Health Companies to the Personalized Medicine Market
- 7.7 Change to the Big Pharma Business Model
- 7.8 Cost-effectiveness and Business Value of Personalized Medicine
- 7.9 Comparative Effectiveness Research in Personalized Medicine

8 PERSONALIZED MEDICINE MAIN INDUSTRY PLAYERS

- 8.1 23andMe
- 8.2 Affymetrix
- 8.3 Astex Pharmaceuticals
- 8.4 Atossa Genetics
- 8.5 CuraGen
- 8.6 Celera Corporation (Quest Diagnostics)
- 8.7 Celldex Therapeutics
- 8.8 deCode Genetics (Amgen)
- 8.9 Illumina
- 8.10 Genelex
- 8.11 Myriad
- 8.12 Nodality
- 8.13 Qiagen

9 PERSONALIZED MEDICINE INDUSTRY PRODUCTS AND KITS

- 9.1 23andme
- 9.2 Affymetrix

9.3 Astex Pharmaceuticals

9.4 Atossa Genetics

9.4.1 Mammary Aspirate Specimen Cytology Test (MASCT™)

9.4.2 ForeCYTE Breast Health Test (SM)

9.4.3 ArgusCYTE Breast Health Test(SM)

9.4.4 FullCYTE Breast Health Test

9.4.5 NextCYTE Breast Health Test

9.5 Celera (Quest Diagnostics)

9.5.1 ViroSeq® HIV-1 Genotyping System

9.5.2 ViroSeq® HIV-1 Integrase Assay

9.5.3 ViroSeq® HCV Assay

9.5.4 ViroSeq® HBV Assay

9.5.5 Cystic Fibrosis Genotyping Assay

9.5.6 LDL-S3GGE® Test

9.5.7 HDL-S10GGE® Test

9.5.8 KIF6-StatinCheck™ Genotype Test

9.5.9 9p21-EarlyMICheck™ Genotype Test

9.5.10 LPA-AspirinCheck™ Genotype Test

9.5.11 AlleleSEQR® HLA PCR/Sequencing Kits

9.5.12 m2000® RealTime PCR System

9.5.13 CEGA -16™ Instrument

9.6 deCode Genetics

9.6.1 deCodeT2 Genetic Test

9.6.2 deCODE Breast Cancer™

9.6.3 deCODE Prostate Cancer™

9.6.4 deCODE AF™

9.6.5 deCODE Glaucoma™

9.6.6 deCODE MI™

9.6.7 deCODE Complete™

9.6.8 deCODE Cancer™

9.6.9 deCODE Cardio™

9.6.10 deCODE Services

9.7 Illumina

9.7.1 Illumina HiSeq 2000/1000

9.7.2 Genome Analyzer IIX

9.7.3 Illumina MiSeq

9.7.4 Illumina HiScanHQ

9.7.5 Illumina HiScan and iScan Array

9.8 Genelex

- 9.8.1 You Script™
- 9.9 Myriad Genetics
 - 9.9.1 BRACAnalysis®
 - 9.9.2 COLARIS®/COLARIS AP®
 - 9.9.3 MELARIS®
 - 9.9.4 PANEXIA®
 - 9.9.5 OnDose®
 - 9.9.6 PREZEON™
 - 9.9.7 THERAGUIDE® 5FU
 - 9.9.8 Prolaris®
- 9.10 Nodility
- 9.11 Qiagen
 - 9.11.1 Genotyping Products
 - 9.11.2 QIASymphony Platform

10 PERSONALIZED MEDICINE MARKET ANALYSIS

- 10.1 General Overview
- 10.2 Personalized Medicine Market Forecast
- 10.3 Personalized Medical Care Market Forecast
- 10.4 Personalized Medicine -Nutrition and Wellness Sub-Market Forecast
- 10.5 Personalized Medicine -Diagnostic and Therapeutic Sub-Market Forecast
- 10.6 Global Personalized Medical Technology Market Forecast
- 10.7 Global Personalized Medicine Sub-market Growth Forecast
- 10.8 Molecular Diagnostics Market
- 10.9 Consumer Genomics Market
- 10.10 Market Participant Analysis
 - 10.10.1 23andme
 - 10.10.2 Affymetrix
 - 10.10.3 Astex Pharmaceuticals
 - 10.10.4 Atossa Genetics
 - 10.10.5 Celera (Quest Diagnostics)
 - 10.10.6 Celldex Therapeutics
 - 10.10.7 deCode Genetics (Amgen)
 - 10.10.8 Illumina
 - 10.10.9 Genelex
 - 10.10.10 Myriad
 - 10.10.11 Nodality
 - 10.10.12 Qiagen

11 STRENGTHS AND ADVANTAGES OF PERSONALIZED MEDICINE

- 11.1 Sequencing of the Human Genome in 2000
- 11.2 Improving Patient Care and Reducing Side Effects
- 11.3 Personalized Medicine will Reduce Healthcare Costs
- 11.4 FDA Advances in Personalized Medicine Regulation
- 11.5 Advancing Technologies
 - 11.5.1 Next Generation Sequencing
- 11.6 Industry Investing in Pharmacogenomics
- 11.7 Consumer Genomics and POC Market
- 11.8 Oncology a Driving Force of Personalized Medicine

12 RESTRAINTS OF THE PERSONALIZED MEDICINE MARKET

- 12.1 Lack of Sufficient Regulation
- 12.2 Lack of Sufficient Genotypic Linkage Studies to Disease Phenotype
- 12.3 Reimbursement Issues

13 PERSONALIZED MEDICINE AND REGULATORY POLICIES

- 13.1 Regulation
- 13.2 Genetic Information Non-discrimination Act (GINA)
- 13.3 FDA Advancements on Genetic Testing Approval
- 13.4 FDA- New Models to Assess Gene Therapy Safety
- 13.5 FDA- Companion Diagnostics
- 13.6 FDA - Partnership in Applied Comparative Effectiveness Science (PACES) Initiative

14 FINAL SUMMARY AND FUTURE PERSPECTIVES

List Of Tables

LIST OF TABLES

- Table 2.1: Quick Facts: Personalized Medicine
- Table 2.2: Genetic Mutations that Predispose Individuals to Disease
- Table 2.3: Potential Applications of Pharmacogenetics and Pharmacogenomics in Personalized Medicine
- Table 2.4: Main Cytochrome P450 Enzymes Involved in Drug Metabolism
- Table 2.5: QUICK FACTS: Rapid & Slow Metabolizer Phenotypes
- Table 2.6: Population Frequency of Cytochrome P450(CYP) 2C19 Metabolizer Types
- Table 2.7: Population Frequency of Cytochrome P450 (CYP) Metabolizer Types
- Table 2.8: Depression Medications Affected by Genetic Mutations
- Table 2.9: Cardiovascular Medications Affected by Genetic Mutations
- Table 2.10: Cancer Medications that may be Affected by Genetic Mutations
- Table 2.11: Diabetes Medications Affected by Genetic Mutations
- Table 2.12: Anti-Epileptic Drugs Affected by Genetic Mutations
- Table 2.13: Anti-Retroviral Drugs Affected by Genetic Mutations
- Table 2.14: Anti-Reflux/Ulcer Drugs Affected by Genetic Mutations
- Table 2.15: List of Therapeutics According to Cytochrome P450 Subtype Metabolism
- Table 2.16: Cytochrome (CYP) P450 Drug-Interactions Inhibitor List
- Table 2.17: Cytochrome (CYP) P450 Drug-Interactions Inducer List
- Table 2.18: QUICK FACTS - Main Aims of Pharmacogenomics
- Table 2.19: How Pharmacogenomics has Influenced the Top Ten Selling Drugs Globally
- Table 2.20: Advantages, Disadvantages and Cost of Popular Genotyping Methods
- Table 2.21: QUICK FACTS - Top Ten Pharmacogenomics Tests
- Table 2.22: QUICK FACTS - FDA Accepted Pharmacogenomic Biomarkers
- Table 2.23: QUICK FACTS - Benefits of Single Base Primer Extension in Pharmacogenetics
- Table 2.24: Future Applications of Ultra-High Throughput Sequencing
- Table 2.25: QUICK FACTS - Comparison of Genotyping Techniques
- Table 2.26: Problems associated with Microarray Sequencing
- Table 2.27: QUICK-FACTS - Top Ten Genetic Findings of 2010 by 23andMe
- Table 2.28: FDA Companion Diagnostics Device List: In Vitro and Imaging Tools
- Table 2.29: Important Strategies for a Successful Companion Diagnostic Launch
- Table 3.1: Predicted Warfarin Concentrations depending on CYP2C9 and VKORC1 Genotype
- Table 3.2: QUICKFACTS - Top Five Most Frequent Cancers in Men and Women, Globally

- Table 3.3: QUICKFACTs - Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer per Country, Worldwide
- Table 3.4: QUICK-FACTS - Types of Diagnostic Tests Available to Determine HER2 Status in Breast Cancer Patients
- Table 3.5: Validated HER2 Tests for Cancer
- Table 3.6: QUICK FACTS - Advantages and limitations of IHC HER2 testing applied to breast cancer
- Table 3.7: In-Situ Hybridization Determination of HER2 Expression by PathVysion® and HER2 FISH pharmDx™
- Table 3.8: HER2 CISH Determination
- Table 3.9: Validated FISH Kits for HER2 Testing in Breast Cancer
- Table 3.10: Validated SISH Kits for HER2 Testing in Breast Cancer
- Table 3.11: Validated CISH Kits for HER2 Testing in Breast Cancer
- Table 3.12: Advantages and limitations of ISH techniques applied to HER2 testing in breast cancer
- Table 3.13: QUICK FACTS- Prevalence of Deleterious Mutations in BRCA1 and BRCA2 Genes
- Table 3.14: QUICK FACTS- prevalence of deleterious mutations in BRCA1 and BRCA2 in individuals of Ashkenazi Ancestry
- Table 3.15: QUICK FACTS- Risk Factors for Hereditary Breast and Ovarian Cancer (HBOC)
- Table 3.17: QUICKFACTs- BRACAnalysis® Panel of Assays
- Table 4.1: QUICKFACTs - Objectives of the Personalized Medicine Coalition
- Table 4.2: Current Personalized Medicine Coalition Members
- Table 4.3: Genetic Variants used in care of melanoma, gastrointestinal stromal tumors, non-small-cell lung cancer, thymic cancer and breast and ovarian cancers.
- Table 4.4: Minimum Definition of a clinically Actionable Variant
- Table 4.5: Minimum Criteria for Whole Genome Analysis in Clinical Laboratory Improvement Amendments Laboratory of Genomic Pathology, Clinical Whole Genome Analysis
- Table 5.1: Public Funding Bodies for Pharmacogenetic/Pharmacogenomic Research
- Table 5.2: North American Companies Involved in Pharmacogenomics/Pharmacogenetics Drug Development and Diagnostics
- Table 5.3: European Companies Involved in Pharmacogenomics/Pharmacogenetics Drug Development and Diagnostics
- Table 5.4: North American Companies Involved in Pharmacogenomics/Pharmacogenetics Diagnostics
- Table 5.5: European & Other Companies Involved in Pharmacogenomics/Pharmacogenetics

Diagnostics

Table 5.6: North American Companies Involved in Pharmacogenomics/Pharmacogenetics Services

Table 5.7: European/Other Companies Involved in Pharmacogenomics/Pharmacogenetics Services

Table 5.8: North American Companies Involved in Pharmacogenomics/Pharmacogenetics Tools Kits and Software

Table 5.9: European Companies Involved in Pharmacogenomics/Pharmacogenetics Tools Kits and Software

Table 5.10: North American Companies with Minor interest in Pharmacogenomics/Pharmacogenetics

Table 5.11: European/Other Companies with Minor interest in Pharmacogenomics/Pharmacogenetics

Table 5.12: Large US Companies with Investment into Pharmacogenomics/Pharmacogenetics

Table 5.13: Large European Companies with Investment into Pharmacogenomics/Pharmacogenetics

Table 5.14: Large Japanese Companies with Investment into Pharmacogenomics/Pharmacogenetics

Table 5.15: Top Ten Biological Areas of Interest in Pharmacogenetics/Pharmacogenomics

Table 5.16: Top International Pharmacogenetic/Pharmacogenomic Research Institutions

Table 5.17: Top European Pharmacogenetic/Pharmacogenomic Research Institutions

Table 6.1: QUICK FACTS- Variation of Reimbursement Policies for HER2 and KRAS Testing in Europe

Table 6.2: Pharmaceutical Companies Providing Subsidization of Diagnostic Personalized Medicine Tests in Europe

Table 6.3: QUICKFACTS - Challenges Within Personalized Medicine Market in Europe

Table 6.4: QUICKFACTS- Function of the European network for Health Technology Assessment (EUnetHTA) Organisation

Table 6.5: European network for Health Technology Assessment (EUnetHTA) Partners

Table 6.6: European network for Health Technology Assessment (EUnetHTA) Associates

Table 6.7: Diagnostics Guidance Assessment by the National Institute for Health and Clinical Excellence (NICE)

Table 6.8: Current Diagnostics Guidance in Development by the Diagnostics Access Program, UK

Table 6.9: Published Diagnostics Guidance by the Diagnostics Access Program, UK

Table 6.10: Medical Technologies Guidance Assessment by the National Institute for Health and Clinical Excellence (NICE)

Table 6.11: Published Medical Technologies Guidance by the National Institute for Health and Clinical Excellence (NICE)

Table 6.12: Published Medical Technologies Guidance in Development by the National Institute for Health and Clinical Excellence (NICE)

Table 6.13: QUICK FACTS - Key Challenges to Personalized Medicine

Table 6.14: QUICKFACTS - Personalized Medicine - Translation into Medical Applications

Table 7.1: QUICK FACTS - Major Market Trends in Personalized Medicine

Table 7.2: Collaboration Strategies Required between Industry, Payers and Governments for a Productive Personalized Medicine Market

Table 7.3: QUICK FACTS - Business Model Recommendations for Diagnostic, Pharmaceutical and Biotechnology Companies

Table 7.4: QUICK FACTS - Business Model Recommendations for Providers. Provider Systems and Academic Medical Centres

Table 7.5: QUICK FACTS Business Model Recommendations for Payers

Table 7.6: QUICK FACTS - Business Model Recommendations for Governments

Table 7.7: QUICK FACTS - Non-Healthcare Companies with Potential to enter the Personalized Medicine Market

Table 7.8: Hurdles of Personalised Medicine with Respect to Cost-Effectiveness

Table 8.1: Patent Listing of Affymetrix Array technology

Table 8.2: Patent Listing of Affymetrix Genotyping Technology

Table 8.3: Patent Listing of Affymetrix Array technology

Table 8.4: Patent Listing of Affymetrix Genotyping Technology

Table 8.5 Astex Pharmaceuticals Pipeline Portfolio 104

Table 8.6: Astex Pharmaceuticals Pipeline Portfolio Funded Completely by Partner Companies

Table 8.7: Potential Business Partnerships of Celldex Therapeutics

Table 8.8: Illumina Core Technologies

Table 8.9: Illumina Core Technology Applications

Table 8.10: Illumina Instrument Product Portfolio

Table 8.11: Illumina Assay Product Portfolio

Table 8.12: Genetic Test Panel Available from Genelex for Research Institutions and Clinical Trials

Table 8.13: Pre-Clinical, Clinical and Commercial Applications of SCNPs by Nodality

Table 8.14: Qiagen Timeline of Events, 1994-2012

Table 8.15: QUICKFACTS - Range of Product Groups from Qiagen

Table 9.1: 23andMe Disease Risk Genetic Test Panel

- Table 9.2: 23andMe Carrier Status Genetic Test Panel
- Table 9.3: 23andMe Drug Response Genetic Marker Test Panel
- Table 9.4: 23andMe Genetic Traits Test Panel
- Table 9.5: QUICKFACTs - Product Overview of Affymetrix
- Table 9.6: Microarray Products by Affymetrix
- Table 9.7: Affymetrix Research Services Laboratory (ARSL) Premier Services
- Table 9.8: Genetic Applications of Axiom® Technology by Affymetrix
- Table 9.9: Range of Small Molecule Therapeutics Available from Astex Pharmaceuticals
- Table 9.10: Panel of cystic fibrosis transmembrane conductance regulator (CFTR) mutations screened for in Celera Cystic Fibrosis Genotyping Assay
- Table 9.11: Genetic Tests Available from BHL/Celera
- Table 9.12: Panel of BHL Clinical Diagnostic Tests
- Table 9.13: Features of the m2000® RealTime PCR System by Celera
- Table 9.14: Genetic Diagnostic Tests Available from deCode Genetics
- Table 9.15: Type 2 Diabetes risk range and distribution according to continental ancestry as Determined by deCodeT2 Genetic Test
- Table 9.16: Genetic Mutations Identified by the deCODE MI™ Test in a European Population
- Table 9.17: Genetic Mutations Identified by the deCODE MI™ Test in an East Asian Population
- Table 9.18: Disease States that are Included in the deCODE Complete™ Genetic Screen
- Table 9.19: Panel of Diseases Screened for in the deCODE Cancer™ Test
- Table 9.20: Panel of Cardiovascular Diseases in the deCODE Cardio™ Test
- Table 9.21: deCODE Genetics Genotyping and Sequencing Service
- Table 9.22: deCODE Genetics Data Management, Protection and Storage Service
- Table 9.23: deCODE Genetics Sequence Imputation and Data Analysis Service
- Table 9.24: Illumina HiSeq 2500/1500 Performance Parameters
- Table 9.25: Illumina HiSeq 2000/1000 Performance Parameters
- Table 9.26: Genome Analyzer Ix Performance Parameters
- Table 9.27: Illumina MiSeq Product Specifications
- Table 9.28: Illumina HiScanHQ Product Specifications
- Table 9.29: Illumina HiScan and iScan Array Product Applications
- Table 9.30: Illumina iScan Array Kits
- Table 9.31: Panel of Genetic Screens Available from Genelex
- Table 9.32: Drug Sensitivity Screens Available from Genelex
- Table 9.33: Predictive Genetic Tests Available from Myriad
- Table 9.34: Services offered with BRACAnalysis® Testing from Myriad
- Table 9.35: Advantages of BRACAnalysis® Testing
- Table 9.36: COLARIS® Test Range by Myriad

Table 9.37: COLARIS AP® Test Range by Myriad

Table 9.38: MELARIS® Test Range from Myriad

Table 9.39 Personalized Medicine Tests from Myriad

Table 9.40: OnDose® Testing Procedure from Myriad

Table 9.41: Qiagen Genotyping Products for Sample Collection, stabilization and Storage

Table 9.42: Qiagen Genotyping Products for Genomic DNA Isolation and Purification

Table 9.43: Qiagen Genotyping Products for PCR Based Genotyping Analysis

Table 9.44: Qiagen Products for Genotyping Analysis

Table 9.45: Qiagen Genotyping Products for PCR Detection

Table 9.46: Qiagen Assays for Genetic Analysis

Table 9.47: Qiagen Pyrosequencing-Based Genetic Analysis Products

Table 9.48: Specifications and Features of Qiagen's QIASymphony and QIASymphony RGQ

Table 10.1: QUICK FACTS - Submarkets within the Personalized Medicine Technology Market

Table 10.2: Drug Classes Investigated by 23andMe using genome wide association studies

Table 10.3: QUICKFACTS- Acquisition Profile of Affymetrix

Table 10.4: Genetic Applications of Axiom® Technology by Affymetrix

Table 10.5: Diversified Business Units of Affymetrix

Table 10.6: Celera (Quest Diagnostics) Historic Operating (Loss) (US\$) – Laboratory Services and Products 2008-2010

Table 10.7: Diagnostic Test Product Categories Manufactured by BHL/Celera and Exclusively Distributed by Abbott

Table 10.8: Celldex Therapeutics R&D Expenses (\$) 2010-2012

Table 10.9: Price Listing of Genelex Familial Genetic Tests

Table 10.10: Myriad - Core Business Decisions and Impact on Industry 2012

Table 10.11: Future Test Portfolio of Myriad

Table 11.1: QUICK FACTS: Strengths and Advantages of Genotyping Techniques

Table 11.2: QUICK FACTS: Strengths, Drivers and Advantages of Personalized Medicine Market

Table 12.1: QUICKFACTS: Restraints of Personalized Medicine Market

Table 13.1: QUICK FACTS - Summary of Clinical Laboratory Improvement Amendments (CLIA)

Table 13.2: Clinical Laboratory Improvement Amendments (CLIA) Testing Categories

Table 13.3: QUICK FACTS - Test Features required prior to FDA Approval and Clearance

Table 13.4: Impact of Genetic Information Non-discrimination Act (GINA) on Healthcare Companies and Health Plans

Table 13.5: Impact of Genetic Information Non-discrimination Act (GINA) on US Employers, employment agencies, labor organizations and training programs

Table 13.6: QUICK FACTS - FDA Commitment to the Personalized Medicine Industry

Table 13.7: Objectives of the 'Advancing Regulatory Science at FDA: A Strategic Plan'

Table 13.8: QUICKFACTS - Implementation Strategy of the FDA to Advance Regulatory Science - Develop better Models of Human Adverse response

Table 13.9: QUICKFACTS - Implementation Strategy of the FDA to Advance Regulatory Science - Identify and evaluate biomarkers and endpoints that can be used in non-clinical and clinical evaluations

Table 13.10: QUICKFACTS - Implementation Strategy of the FDA to Advance Regulatory Science - Use and develop computational methods and in silico modelling

List Of Figures

LIST OF FIGURES

- Figure 2.1: QUICK FACTS - Elements of Personalized Genomic Medicine
- Figure 2.2: Identification of Good and Non-Responders in a Patient Population
- Figure 2.3: Pharmacodynamic and Pharmacokinetic Examples of Drug Targets and Drug metabolism in Pharmacogenomics
- Figure 2.4: QUICK FACTS - Flow Diagram of Pharmacogenetic Analysis
- Figure 2.5: Primer Based Base Extension in Pharmacogenetics
- Figure 2.6: Genetic Mutation Detection by Hybridization
- Figure 2.7: Ligation based SNP Detection
- Figure 2.8: New-Generation Sequencing: Pyrosequencing
- Figure 3.1: QUICK FACTS - Warfarin Metabolism and Response
- Figure 3.2: QUICK FACTS - Percentage Frequency of CYP2C9 and VKORC1 mutations in Caucasian, African-American and Asian Populations
- Figure 3.3: QUICK FACTS: Anti-EGFR Therapy and KRAS Mutations
- Figure 3.4: KRAS and BRAF Genetic Tests Available from Asuragen
- Figure 3.5: Global Incidence and Mortality of Cancer in Women
- Figure 3.6: Cancer Deaths in Women, Globally according to Cancer Type
- Figure 3.7: Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer Globally
- Figure 3.8: HER2 Testing Algorithm for Breast Cancer
- Figure 3.9: HER2 Cellular Signalling
- Figure 3.10: QUICKFACTS - Herceptin – Mechanism of Action
- Figure 3.11: BRCA Mutation Increases the Risk of Breast and Ovarian Cancer
- Figure 3.12: Proactive Cancer Management and Preventative Measures Reduces the Risks of Developing BRCA-associated Breast and Ovarian Cancer
- Figure 4.1: Integration of Multiple components for a Personalized Medicine Healthcare System
- Figure 4.2: Workflow Diagram illustrating Clinical Laboratory Improvement Amendments-Certified Laboratory of Genomic Pathology
- Figure 4.3: Hypothetical Flow Diagram of a Patient through the Genomic Pathology Clinical Laboratory
- Figure 5.1: Personalized Medicine Scheme Interaction with Industry, Regulatory Bodies and Funding Agencies
- Figure 5.2: Number of Publically Funded Pharmacogenetic and Pharmacogenomic Research Teams Internationally
- Figure 6.1: Adverse Drug Reactions are the Fourth Leading Cause of Death

- Figure 6.2: Efficacy Rate of Major Disease Types with Standard Treatment
- Figure 6.3: The In Vitro Diagnostic Market in Europe
- Figure 6.4: QUICK FACTS: Organization of the European network for Health Technology Assessment (EUnetHTA)
- Figure 6.5: Key Differences in Reimbursement Policy Approaches for Oncology Diagnostics and Therapeutics in Europe and the US
- Figure 6.6: Flow Diagram of the German Healthcare System and Key Agencies
- Figure 6.7: German Reimbursement Arrangement, Process and Implications
- Figure 7.1: Annual Healthcare Expenditure for Major Industrial Nations
- Figure 7.2: Estimated Life Expectancy from Birth for Major Industrialized Countries
- Figure 8.1: Celldex Therapeutics Product Pipeline
- Figure 8.2: Single Cell Network Profiling (SCNP) Technology by Nodality
- Figure 8.3: Developed Functional Assays that Nodality has explored using new SCNP Technology
- Figure 9.1: Flow Diagram of Celera CEQA -16™ Instrument for Cystic Fibrosis Gene Analysis
- Figure 9.2: Percentage of Individual Populations who have an Increased Risk of Developing Type 2 Diabetes as Determined Using the deCodeT2 Genetic Test
- Figure 9.3: Illumina New Generation Sequencing Technology Workflow Station
- Figure 10.1: Combined Personalized Medicine Market in the US, 2009-2015
- Figure 10.2: Core Personalized Medicine Sub-Market Growth Forecast 2009-2015
- Figure 10.3: Personalized Medical Care Sub-Market Growth Forecast 2009-2015
- Figure 10.4: Nutrition and Wellness Sub-market of Personalized Medicine Growth Forecast 2009-2015
- Figure 10.5: Diagnostic and Therapeutic Personalized Medicine Market Growth Projection in the US, 2009-2015
- Figure 10.6: Global Market Personalized Medicine Technology Growth Forecast 2009-2015
- Figure 10.7: Global Personalized Sub-market Growth Forecast 2009-2014
- Figure 10.8: Personalized Medicine Sub-Market Share (Percentage) 2009
- Figure 10.9: Personalized Medicine Sub-Market Share (Percentage) 2014
- Figure 10.10: Global Molecular Diagnostics Predicted Market Share 2015
- Figure 10.11: Global Molecular Diagnostics Market Projection 2015
- Figure 10.12: Private Funding Gained by 23andMe 2007-2012
- Figure 10.13: Affymetrix Revenue by Business Segment (Percentage), 2012
- Figure 10.14: Affymetrix Total Revenue 2007-2012
- Figure 10.15: Affymetrix Revenue by Product Division – Consumables, Instruments 2010-2012
- Figure 10.16: Affymetrix Core Product Sales – Gene Expression, Genetic Analysis &

Clinical Applications and Life Science Reagents, 2011-2012

Figure 10.17: Affymetrix Revenue Derived from Outside the US, 2009-2012

Figure 10.18: Affymetrix Revenue Derived from the US, 2009-2012

Figure 10.19: Affymetrix Net Loss, 2009-2012

Figure 10.20: Affymetrix Research and Development Funding, 2009-2012

Figure 10.21: Affymetrix Revenue Generated within USA (Percentage) 2010-2012

Figure 10.22: Astex Pharmaceuticals Priority Pipeline Products SGI-110 and AT13387 by Indication, Clinical Phase and Timeline

Figure 10.23: Astex Pharmaceuticals Revenue Generated 2008-2012

Figure 10.24: Astex Pharmaceuticals Net Income 2009-2012

Figure 10.25: Atossa Genetics Total Revenue (US\$) 2011, 2012

Figure 10.26: Atossa Genetics Revenue (US\$) Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012

Figure 10.27: Atossa Genetics Percentage Revenue Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012

Figure 10.28: Quest Diagnostics Revenue (\$ Billions) 2008-2012

Figure 10.29: Quest Diagnostics Operating Revenue (\$ Billions) 2008-2012

Figure 10.30: Quest Diagnostics Net Income (\$ Billions) 2008-2012

Figure 10.31: Celera (Quest Diagnostics) Historic Revenue Generated 2008-2010

Figure 10.32: Celera (Quest Diagnostics) Historic Gross Margin Generated 2008-2010

Figure 10.33: Celera (Quest Diagnostics) Historic Revenue Generated– Laboratory Services and Products 2008-2010

Figure 10.34: Celera (Quest Diagnostics) Historic Revenue (%)Generated by Distribution Agreement with Abbott 2008-2010

Figure 10.35: Celera (Quest Diagnostics) Historic Research and Development Spending 2008-2010

Figure 10.36: deCode Genetics Historic Net Loss Incurred 2004-2008

Figure 10.37: Illumina Revenue Generated (\$ Billions) 2010-2012

Figure 10.38: Illumina Net Income Generated (\$ Billions) 2010-2012

Figure 10.39: Myriad Revenue Generated 2007-2013

Figure 10.40: Operating Income Generated by Myriad 2007-2012

Figure 10.41: Myriad Revenue Generated by Molecular Diagnostic Testing and Companion Diagnostic Services, 2012

Figure 10.42: Future Molecular Diagnostic Pipeline of Myriad

Figure 10.43: Customer Profile of Qiagen – Percentage of Net Sales 2012

Figure 10.44: Qiagen Global Net Sales 2007-2012

Figure 10.45: Qiagen Operating Income 2007-2012

Figure 10.46: Qiagen Global Net Income 2007-2012

Figure 11.1: Percentage Oncology (Lung, Colorectal, Breast, Prostate) Patients Undergoing Next Generation Sequencing Testing in the US, 2018

Figure 11.2: Pipeline and On-market Oncology (Lung, Breast, Colorectal, Prostate) Therapeutics Directed Against Specific Mutations, 2013

I would like to order

Product name: Personalized Medicine and Companion Diagnostic Market Q2 2013- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

Product link: <https://marketpublishers.com/r/P40B3A29BD7EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P40B3A29BD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

